Monoclonal antibodies inhibiting the T cell checkpoints CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) and PD-1 have shown antitumor immune responses, resulting in pronounced efficacy in a small percentage of patients with cancer (50, 51). This evidence concerns the gene PDCD1 and cancer.